Report Details
Report by La Merie Business Intelligence
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated with a drug payload for treatment of cancer as of July 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The humanized anti-Her2 monoclonal antibody Herceptin (trastuzumab) has become the mainstay in the treatment of Her2-positive breast cancer. Combining trastuzumab with the potent cytotoxic DM1 via a stable linker resulted in the antibody-drug conjugate (ADC) trastuzumab-DM1. Genentech and Roche are conducting phase III trials of trastuzumab-DM1 in women with advanced HER2-positive breast cancer whose disease has progressed after receiving initial treatment. Results of previous phase II investigation showed an impressive 33 % objective response rate in 110 women with advanced (metastatic) HER2-positive breast cancer that had worsened despite having already received an average of seven drugs for metastatic disease, including chemotherapy, trastuzumab and lapatinib. These data highlight the enormous potential of ADCs in the treatment of cancer although the first ADC approved by the FDA voluntarily will be withdrawn from the market. The required post-marketing study did not confirm the clinical benefit of Mylotarg in previously untreated AML.
With two ADCs in phase III evaluation and at least 16 different ADCs in clinical phase I and II evaluation, ADC technology is on the verge of becoming an established antibody potentiation technology of great interest for providers of the technology and antibody developers. Improvements in linker technology, progress with the cytotoxic payload and more diligently designed and executed clinical studies will contribute to the success of the technology.
The report includes a compilation of current active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Index
Antibody-Drug Conjugates (ADC)
Other Immunoconjugates in Oncology
Recent ADC R&D Agreements
Corporate Antibody-Drug Conjugate R&D Pipelines
About La Merie
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.